European guideline on chronic pruritus: In cooperation with the European dermatology forum (EDF) and the European academy of dermatology and venereology (EADV)

Acta Dermato-Venereologica

Volumn 92, Issue 5, 2012, Pages 563-581

  Weisshaar, Elke ^a   Szepietowski, Jacek C ^b   Darsow, Ulf ^c   Misery, Laurent ^d   Wallengren, Joanna ^e   Mettang, Thomas ^f   Gieler, Uwe ^g   Lotti, Torello ^h   Lambert, Julien ⁱ   Maisel, Peter ^j   Streit, Markus ^k   Greaves, Malcolm W ^l   Carmi Chael, Andrew ^m   Tschachler, Erwin ⁿ   Ring, Johannes ^c   Ständer, Sonja ^j  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Department of Dermatology   (France)

^e LUND UNIVERSITY   (Sweden)

^f DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

^j UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^k CANTONAL HOSPITAL AARAU   (Switzerland)

^l ST THOMAS HOSPITAL   (United Kingdom)

^m JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

ⁿ Universitatsklinik fur Dermatologie   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; BENZOCAINE; CAPSAICIN; COLESTYRAMINE; CROMOGLYCATE DISODIUM; ENDOCANNABINOID; ERYTHROPOIETIN; ETANERCEPT; FLUOXETINE; GABAPENTIN; GAMMA LINOLENIC ACID; KETOTIFEN; LIDOCAINE; LIPID; MIRTAZAPINE; NALFURAFINE; NALMEFENE; NALOXONE; NALTREXONE; ONDANSETRON; PAROXETINE; PHENOBARBITAL; PRILOCAINE; RIFAMPICIN; SERTRALINE; STANOZOLOL; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUPUNCTURE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ATOPIC ERUPTION OF PREGNANCY; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW BIOPSY; BRACIORADIAL PRURITUS; BRAIN INFARCTION; BRAIN TUMOR; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC PRURITUS; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DEPRESSION; DERMATITIS; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG ACTIVITY; DRUG INDUCED DISEASE; EATING DISORDER; ELECTROENCEPHALOGRAPHY; ELECTRON MICROSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FERRITIN BLOOD LEVEL; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HALLUCINOSIS; HELMINTHIASIS; HEPATITIS B; HEPATITIS C; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOELECTROPHORESIS; INTRAHEPATIC CHOLESTASIS OF PREGNANCY; IRON BLOOD LEVEL; IRON DEFICIENCY; LABORATORY TEST; LIOTHYRONINE BLOOD LEVEL; LIVER TRANSPLANTATION; MEDICAL HISTORY; MOOD DISORDER; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NOTALGIA PARESTHETICA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; OCCULT BLOOD TEST; PARASITOSIS; PATIENT EDUCATION; PEMPHIGOID GESTATIONIS; PHOTOTHERAPY; POLYCYTHEMIA VERA; POLYMORPHIC ERUPTION OF PREGNANCY; POSITRON EMISSION TOMOGRAPHY; POSTZOSTERIC NEURALGIA; PRACTICE GUIDELINE; PREGNANCY DISORDER; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSYCHOSOCIAL REHABILITATION; RELAXATION TRAINING; SCHIZOPHRENIA; SEROLOGY; THORAX RADIOGRAPHY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TOXOCARIASIS; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND; ULTRAVIOLET B RADIATION; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WESTERN BLOTTING;

CHRONIC DISEASE; CONSENSUS; DERMATOLOGY; EUROPE; HUMANS; PREDICTIVE VALUE OF TESTS; PRURITUS; RISK FACTORS;

EID: 84868361593     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1400     Document Type: Article

References (296)

1. Weisshaar EW, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 2009; 89: 339-350.
2. Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classifcation of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87: 291-294.
3. Ständer S, Weisshaar E, Mettang T, Streit M, Darsow U, Schneider G, et al. Klinische Klassifkation von chro-nischem pruritus. Interdisziplinarer konsensusvorschlag fur einen diagnostischen Algorithmus. hautarzt 2006; 57: 390-394.
4. Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, oranje A, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317-328.
5. Misery L, Alexandre S, Dutray S, Chastaing M, Consoli SG, Audra H, et al. Functional itch disorder or psychogenic pruritus: suggested diagnosis criteria from the French psychodermatology group. Acta Derm Venereol 2007; 87: 341-344.
6. Magerl M, borzova E, giménez-Arnau A, grattan CEh, Lawlor F, Mathelier-Fusade P, et al. The defnition and diagnostic testing of physical and cholinergic urticarias 2009; EAAC/gA_LEN/EDF/UNEV consensus panel recommendations. Allergy 2009; 64: 1715-1721.
7. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J prev Soc Med 1976; 30: 107-114.
8. Zylicz Z, Twycross R, Jones EA. Pruritus in advanced disease. oxford: oxford University press; 2004.
9. Dalgard F, Svensson A, Holm JO, Sundby J. Self-reported skin morbidity in oslo. Associations with sociodemograp-hic factors among adults in a cross-sectional study. Br J Dermatol 2004; 151: 452-457.
10. Dalgard F, Dawn AG, Yosipovitch G. Are itch and chronic pain associated in adults? results of a large population survey in Norway. Dermatology 2007; 214: 305-309.
11. Matterne U, Apfelbacher C, Loerbroks A. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol 2011; 91: 674-679.
12. Ständer S, Schäfer I, Phan NQ, Blome C, Herberger K, Heigel H, et al. Prevalence of chronic pruritus in germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 2010; 221: 229-235.
13. Yosipovitch G, Goon AT, Wee J, Chan YH, Zucker I, Goh CL. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol 2002; 41: 212-216.
14. Szepietowski JC, Reich A, Wisnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat 2002; 10: 221-226.
15. Szepietowski JC, Reich A, Wisnicka B. Pruritus and psoriasis. Br J Dermatol 2004; 151: 1284.
16. Szepietowski JC, Salomon J. Uremic pruritus: still an important clinical problem. J Am Acad Dermatol 2004; 51: 842-843.
17. Britt H, Pan Y, Miller GC, Valenti L, Charles J, Knox S,et al. presentations of 'itch' in Australian general practice. Aust Fam physician 2004; 33: 488.
18. McCormick A, Fleming D, Charlton J. Morbidity Statistics from general practice. Fourth national study 1991-1992. London: Her Majestic's Stationery Offce; 1995.
19. Symvoulakis EK, Krasagakis K, Komninos ID, Kastrinakis I, Lyronis I, Philalithis A, et al. Primary care and pattern of skin diseases in a Mediterranean island. Bmc Fam pract 2006; 7: 6.
20. Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, et al. The role of micro-infammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 749-755.
21. Blachley JD, Blankenship DM, Menter A, Parker TF, Knochel JP. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J kidney Dis 1985; 5: 237-241.
22. Ståhle-Bäckdahl M, Hagermark O, Lins LE, Torring O, Hilliges M, Johansson O. Experimental and immunohi-stochemical studies on the possible role of parathyroid hormone in uraemic pruritus. J Intern Med 1989; 225: 411-415.
23. Stockenhuber F, Sunder-plassmann G, Balcke P. Increased plasma histamine levels in chronic renal failure. N Engl J Med 1987; 317: 386.
24. Dugas-Breit S, Schopf P, Dugas M, Schiff H, Rueff F, Przybilla B. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol ges 2005; 3: 343-347.
25. Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al. kappa-opioid system in uremic pruritus: multi-center, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16: 3742-3747.
26. Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348: 1552-1554.
27. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11: 514-519.
28. Duque MI, Thevarajah S, Chan YH, Tuttle AB, Freedman BI, Yosipovitch G. Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 2006; 66: 184-191.
29. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus - new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17: 1558-1563.
30. Bergasa NV. The pruritus of cholestasis. J hepatol 2005; 43: 1078-1088.
31. Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres best pract res Clin gastroenterol 2000; 14: 643-655.
32. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment Virus C. Arthritis rheum 1999; 42: 2204-2212.
33. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27: 679-684.
34. Kremer AE, Dijk RV, Leckie P, Schaap FG, Kuiper EM, Mettang T, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. Hepatology 2012 (Epub ahead of print).
35. Neilly JB, Martin A, Simpson N, MacCuish AC. Pruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control. Diabetes Care 1986; 9: 273-275.
36. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 2003; 4: 315-331.
37. Caravati CM, Jr., Richardson DR, Wood BT, Cawley EP. Cutaneous manifestations of hyperthyroidism. South Med J 1969; 62: 1127-1130.
38. Adams S. Iron defciency, serum ferritin, generalized pruritus and systemic disease: a case control study. Br J Dermatol 1989; 121: 15.
39. Nestler JE. Hemochromatosis and Pruritus. Ann Intern Med 1983; 98: 1026.
40. Hamilton DV, Gould DJ. Generalized pruritus as a presentation of idiopathic haemochromatosis. Br J Dermatol 1985; 112: 629.
41. Bernhard JD. Itch: Mechanisms and management of pruritus. New york: Mcgraw-hill; 1994.
42. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J haematol 2001; 115: 619-621.
43. Egli F, Wieczorek A, Niemoller M, Rhyner K. Polycythaemia vera: klinik und verlauf bei 86 patienten. Schweiz Med Wochenschr 1988; 118: 1969-1975.
44. Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. blood 1966; 28: 795-806.
45. Pieri L, Bogani C, Guglielmelli P, Zingariello M, Rana RA, Bartalucci N, et al. The JAk2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haema-tologica 2009; 94: 1537-1545.
46. Krajnik M, Zylicz Z. Pruritus in advanced internal diseases. pathogenesis and treatment. Neth J Med 2001; 58: 27-40.
47. Brunner W. Pruritus - auch eine internistische he-rausforderung. Schweiz Med Wochenschr 1995; 125: 2244-2250.
48. Gelfand JM, Rudikoff D. Evaluation and treatment of itching in hIV-infected patients. Mt Sinai J Med 2001; 68: 298-308.
49. Eisman S. pruritic papular eruption in hIV. Dermatol Clin 2006; 24: 449-457.
50. Aff Y, Aubin F, Puzenat E, Degouy A, Aubrion D, Hassam B, et al. Enquete etiologique d'un prurit sine materia: etude prospective d'une serie de 95 patients. Rev Med Interne 2004; 25: 490-493.
51. Canavero S, Bonicalzi V, Massa-Micon B. Central neurogenic pruritus: a literature review. Acta Neurol belg 1997; 97: 244-247.
52. Adreev VC, Petkov I. Skin manifestations associated with tumours of the Brain. Br J Dermatol 1975; 92: 675-678.
53. Savk E, Savk O, Bolukbasi O, Culhaci N, Dikicioglu E, Karaman G, et al. Notalgia paresthetica: a study on pathogenesis. Int J Dermatol 2000; 39: 754-759.
54. Savk O, Savk E. Investigation of spinal pathology in notalgia paresthetica. J AM Acad Dermatol 2005; 52: 1085-1087.
55. Goodkin R, Wingard E, Bernhard JD. Brachioradial pruritus: cervical spine disease and neurogenic/neuropa-thic (corrected) pruritus. J Am Acad Dermatol 2003; 48: 521-524.
56. Marziniak M, Phan NQ, Raap U, Siepmann D, Schurmey-er-horst F, Pogatzki-zahn E, et al. Brachioradial pruritus as a result of cervical spine pathology: the results of a magnetic resonance tomography study. J Am Acad Der-matol 2011; 65: 756-762.
57. Reich A, Ständer S. Drug-induced pruritus: A review. Acta Derm Venereol 2009; 89: 236-244.
58. Kaplan AP. Drug-induced skin disease. J Allergy Clin Immunol 1984; 74: 573-579.
59. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997; 136: 553-559.
60. Beauregard S, Gilchrest BA. A survey of skin problems and skin care regimens in the elderly. Arch Dermatol 1987; 123: 1638-1643.
61. Yalcin B, Tamer E, Toy GG, Oztas P, Hayran M, Alli N. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. Int J Dermatol 2006; 45: 672-676.
62. Thaipisuttikul Y. Pruritic skin diseases in the elderly. J Dermatol 1998; 25: 153-157.
63. Sommer F, Hensen P, Bockenholt B, Metze D, Luger TA, Ständer S. Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol 2007; 87: 510-516.
64. Weisshaar E, Diepgen TL, Luger TA, Seeliger S, Witteler R, Ständer S. Pruritus in pregnancy and childhood - do we really consider all relevant differential diagnoses? Eur J Dermatol 2005; 15: 320-331.
65. Ambros-rudolph CM, Mullegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specifc dermatoses of pregnancy revisited and reclassifed: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54: 395-404.
66. Holmes RC. Polymorphic eruption in pregnancy. Sem Dermatol 1988; 8: 18-22.
67. Girling JC. Obstetric cholestasis. Guideline no 43. London: royal College of obstetricians and gynaecologists (rCog); 2006.
68. Reyes H, gonzalez MC, Ribalta J, Aburto H, Matus C, Schramm G, et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med 1978; 88: 487-493.
69. Reyes H, Taboada G, Ribalta J. Prevalence of intrahepatic cholestasis of pregnancy in La paz, bolivia. J Chronic Dis 1979; 32: 499-504.
70. Clark TJ, Dwarakanath L, Weaver JB. Pruritus in pregnancy and obstetric cholestasis. Hosp Med 1999; 60: 254-260.
71. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933-938.
72. Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, Lob-Corzilius T, et al. Itch intensity evaluated in the german Atopic Dermatitis Intervention Study (gADIS): correlations with quality of life, coping behaviour and SCorAD severity in 823 children. Acta Derm Venereol 2008; 88: 234-239.
73. Halvorsen JA, Dalgard F, Thoresen M, Thoresen M, Bjert-ness E, Lien L. Itch and mental distress: a cross-sectional study among late adolescents. Acta Derm Venereol 2009; 89: 39-44.
74. Lim YL, Chan YH, Yosipovitch G, Greaves MW. Pruritus is a common and signifcant symptom of acne. J Eur Acad Dermatol Venereol 2008; 22: 1332-1336.
75. Reich A, Trybucka K, Tracinska A, Samotij D, Jasiuk B, Srama M, et al. Acne itch: do acne patients suffer from itching? Acta Derm Venereol 2008; 88: 38-42.
76. Weisshaar E, Apfelbacher C, Jager G, Zimmermann E, Bruckner T, Diepgen TL, et al. Pruritus as a leading Symptom: clinical characteristics and quality of life in german and Ugandan patients. BR J Dermatol 2006; 155: 957-964.
77. Schneider G, Driesch G, Heuft G, Evers S, Luger TA, Ständer S. Psychosomatic cofactors and psychiatric co-morbidity in patients with chronic itch. Clin Exp Dermatol 2006; 31: 762-767.
78. Weisshaar E, Gieler U, Kupfer J, Furue M, Saeki H, Yosipovitch G. Questionnaires to Assess Chronic Itch: A Consensus paper of the Special Interest group (SIg) of the International Forum on the Study of Itch (IFSI). Acta Derm Venereol 2012; 92: 493-496.
79. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-507.
80. Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual Analogue Scale: Evaluation of the Instrument for the Assessment of pruritus. Acta Derm Venereol 2012; 92: 497-501.
81. Pfab F, Valet M, Sprenger T, Huss-Marp J, Athanasiadis GI, Baurecht HJ, et al. Temperature modulated histamine-itch in lesional and nonlesional skin in atopic eczema - a combined psychophysical and neuroimaging study. Allergy 2010; 65: 84-94.
82. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, greaves MW, Henz BM, et al. EAACI/gALEN guideline: management of urticaria. Allergy 2005; 61: 321-331.
83. European Association for the Study of the Liver. Clinical practice guideline: Management of cholestatic liver disease. J hepatol 2009; 51: 237-267.
84. Weisshaar E, Forster C, Dotzer M, Heyer G. Experimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgesics in atopic eczema. Skin pharmacol 1997; 10: 183-190.
85. Weisshaar E, Heyer G, Forster C, Hornstein OP, Hand-werker HO. Antipruritugener Effekt antihistaminerger und lokalanasthetischer Externa nach iontophoretischem histaminreiz. Hautarzt 1996; 47: 355-360.
86. Layton AM, Cotterill JA. Notalgia paraesthetica - report of three cases and their treatment. Clin Exp Dermatol 1991; 16: 197-198.
87. Zhai H, Frisch S, Pelosi A, Neibart S, Maibach HI. Antipruritic and thermal sensation effects of hydrocor-tisone creams in human skin. Skin pharmacol Appl Skin physiol 2000; 13: 352-357.
88. Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 2008; 19: 614-618.
89. Al-ghnaniem R, Short K, Pullen A, Fuller LC, Rennie JA, Leather AJ. 1% hydrocortisone oitnment is an effective treatment of pruritus ani: a pilot randomized controlled crossover trial. Int J Colorectal Dis 2007; 22: 1463-1467.
90. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corti-costeroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148: 1212-1221.
91. Szolcsanyi J. Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides 2004; 38: 377-384.
92. Wallengren J, Hakanson R. Effects of capsaicin, bradykinin and prostaglandin E2 in the human skin. Br J Dermatol 1992; 126: 111-117.
93. Lysy J, Sistiery-Ittah M, Israelit Y, Shmueli A, Strauss-Liviatan N, Mindrul V, et al. Topical capsaicin - a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study. Gut 2003; 52: 1323-1326.
94. Wallengren J, Klinker M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol 1995; 32: 287-289.
95. Wallengren J. Brachioradial pruritus: a recurrent solar dermopathy. J Am Acad Dermatol 1998; 39: 803-806.
96. Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993; 29: 438-442.
97. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH, Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986; 15: 504-507.
98. Breneman DL, Cardone JS, Blumsack RF, Lather RM, Searle EA, Pollack VE. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26: 91-94.
99. Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 1996; 72: 617-622.
100. Reimann S, Luger T, Metze D. Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz. Hautarzt 2000; 51: 164-172.
101. Szeimies RM, Stolz W, Wlotzke U, Korting HC, Landthaler M. Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin. Br J Dermatol 1994; 131: 380-382.
102. Hoogenberg K, Tupker RA, van Essen LH, Smit AJ, Kal-lenberg CG. Successful treatment of ulcerating livedo reticularis with infusions of prostacyclin. Br J Dermatol 1992; 127: 64-66.
103. Tupker RA, Coenraads PJ, van der Meer JB. Treatment of prurigo nodularis, chronic prurigo and neurodermatitis circumscripta with topical capsaicin. Acta Derm Venereol 1992; 72: 463.
104. Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44: 471-478.
105. Lotti T, Teofoli P, Tsampau D. Treatment of aquagenic pruritus with topical capsaicin cream. J Am Acad Dermatol 1994; 30: 232-235.
106. Kirby B, Rogers S. Treatment of pUVA itch with capsaicin. Br J Dermatol 1997; 137: 152.
107. Rukwied R, Watkinson A, Mcglone F, Dvorak M. Can-nabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003; 102: 283-288.
108. Dvorak M, Watkinson A, Mcglone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Infamm Res 2003; 52: 238-245.
109. Ständer S, Reinhardt HW, Luger TA. Topische Canna-binoidagonisten. Eine effektive, neue Moglichkeit zur behandlung von chronischem pruritus. hautarzt 2006; 57: 801-807.
110. Szepietowski JC, Szepietowski T, Reich A. Effcacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005; 13: 97-103.
111. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATopA study). J Eur Acad Dermatol Venereol 2008; 22: 73-82.
112. Phan NQ, Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol ges 2010; 8: 88-91.
113. Ständer S, Luger TA. Antipruritische Wirkung von pime-crolimus und Tacrolimus. Hautarzt 2003; 54: 413-417.
114. Fleischer AB, Jr., Boguniewicz M. An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. J Drugs Dermatol 2010; 9: 488-498.
115. Wollina U, Hansel G, Koch A, Abdel-Naser MB. Topical pimecrolimus for skin disease other than atopic dermatitis. Expert opin pharmacother 2006; 7: 1967-1975.
116. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other infammatory skin conditions. Drugs 2005; 65: 827-858.
117. Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen scle-rosus. J Am Acad Dermatol 2011; 64: 99-104.
118. Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol 2011 (Epub ahead of print).
119. Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, et al. Effcacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011; 65: 1-2.
120. Barikbin B, Givrad S, Yousef M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 2009; 34: 776-780.
121. Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. J Am Acad Dermatol 2012; 66: 327-328.
122. Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert rev Clin pharmacol 2012; 5: 91-97.
123. Aguilar-bernier M, Bassas-Vila J, Sanz-Munoz C, Miranda-romero A. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br J Dermatol 2005; 152: 808-809.
124. Pauli-Magnus C, Klumpp S, Alscher DM, kuhlmann U, Mettang T. Short-term effcacy of tacrolimus ointment in severe uremic pruritus. perit Dial Int 2000; 20: 802-803.
125. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterg-hem Y. A prospective proof of concept study of the effcacy of tacrolimus ointment on uraemic pruritus (Up) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004; 19: 1895-1901.
126. Ghorbani AR, Feily A, khalili A, Dormanesh B. Lack of effcacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. Dermatitis 2011; 22: 167-168.
127. Duque MI, Yosipovitch G, Fleischer AB, Jr., Willard J, Freedman BI. Lack of effcacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005; 52: 519-521.
128. Ständer S, Schuermeyer-horst F, Luger T, Weisshaar EW. Treatment of pruritic diseases with topical calcineurin inhibitors. The Clin risk 2006; 2: 213-218.
129. Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol 2001; 45: 910-913.
130. Thomsen JS, Benfeldt E, Jensen SB, Serup J, Menne T. Topically applied aspirin decreases histamine-induced wheal and fare reactions in normal and SLS-infamed skin, but does not decrease itch. A randomized, double-blind and placebo-controlled human study. Acta Derm Venereol 2002; 82: 30-35
131. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study group. J Am Acad Dermatol 1994; 31: 613-616.
132. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study group. Arch Dermatol 1995; 131: 1403-1408.
133. Greenberg Jh. Allergic contact dermatitis from topical doxepin. Contact dermatitis 1995; 33: 281.
134. Shelley WB, Shelley ED, Talanin NY. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996; 34: 143-144.
135. Bonnel RA, LA Grenade L, Karwoski CB, Beitz JG. Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience. J Am Acad Dermatol 2003; 48: 294-296.
136. Welsh AL. Dermatologist ́s handbook. Curtis CA, editor. Springfeld, Illinois: Charls C Thomas. Publisher; 1955.
137. Green BG, Schoen KL. Thermal and nociceptive sensations from menthol and their suppression by dynamic contact. Behav brain res 2007; 176: 284-291.
138. Macpherson LJ, Hwang SW, Miyamoto T, Dubin AE, Patapoutian A, Story GM. More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci 2006; 32: 335-343.
139. Czarnetzki BM, Brechtel B, Braun-Falco O, Christophers E, Schopf E, reckers-Czaschka R, et al. Topical tiacrilast, a potent mast cell degranulation inhibitor, does not improve adult atopic eczema. Dermatology 1993; 187: 112-114.
140. Haider SA. Treatment of atopic eczema in children: clinical trial of 10% sodium cromoglycate ointment. BMJ 1977; 1: 1570-1572.
141. Stainer R, Matthews S, Arshad SH, McDonald S, robinson J, Schapira C, et al. Effcacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial. br J Dermatol 2005; 152: 334-341.
142. O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005; 18: 333-340.
143. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007; 32: 34-38.
144. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Ständer S. Antipruritische Wirksamkeit einer hochdosier-ten Antihistaminika-Therapie: Ergebnisse einer retrospek-tiv analysierten Fallserie. Hautarzt 2009; 60: 564-568.
145. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1-191.
146. Rhoades RB, Leifer KN, Cohan R, Wittig HJ. Suppression of histamine-induced pruritus by three antihistaminic drugs. J Allergy Clin Immunol 1975; 55: 180-185.
147. Arnold AJ, Simpson JG, Jones HE, Ahmed AR. Suppression of histamine-induced pruritus by hydroxyzine and various neuroleptics. J Am Acad Dermatol 1979; 1: 509-512.
148. Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. Eur J Clin pharmacol 1986; 31: 277-280.
149. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34: 1401-1407.
150. Francos GC, kauh YC, Gittlen SD, Schulman ES, Besarab A, Goyal S, et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991; 30: 884-889.
151. Rosner MH. Cromolyn sodium: a potential therapy for uremic pruritus? Hemodial Int 2006; 10: 189-192.
152. Leven A, Naysmith A, Pickens S, Pottage A. Sodium cro-moglycate and hodgkin's pruritus. BMJ 1977; 2: 896.
153. Streit M, Von Felbert V, Braathen LR. Pruritus sine materia. pathophysiologie, Abklarung und Therapie. hautarzt 2002; 53: 830-849.
154. Fjellner B, Hägermark O. Potentiation of histamine-induced itch and fare responses in human skin by the enkephalin analogue Fk-33-824, beta-endorphin and morphine. Arch Dermatol res 1982; 274: 29-37.
155. Phan NQ, Lotts T, Antal A, Bernhard JD, Ständer S. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol 2012; 92: 555-560.
156. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurday-din C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123: 161-167.
157. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41: 431-434.
158. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-549.
159. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, van buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264-1269.
160. Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic u-opioid receptor antagonists. A review. J Am Acad Dermatol 2010; 63: 680-688.
161. Banerji D, Fox R, Seleznick M, Lockey R. Controlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis. J Allergy Clin Immunol 1988; 81: 252.
162. Monroe EW. Effcacy and safety of nalmefene inpatients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 1989; 21: 135-136.
163. Ghura HS, Patterson AD, Carmichael AJ. Naltrexone in the treatment of renal itch. Br J Dermatol 1998; 139: 139.
164. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafne hydrochloride, on severe itch in 337 haemo-dialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010; 25: 1251-1257.
165. Misery L. Gabapentin in dermatology. Dermatology 2005; 211: 79-80.
166. Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J pain Symptom Manage 2004; 28: 396-411.
167. Kanitakis J. Brachioradial pruritus: report of a new case responding to gabapentin. Eur J Dermatol 2006; 16: 311-312.
168. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006; 55: 543-544.
169. Mendham JE. Gabapentin for the treatment of itching produced by burns and wound healing in children: a pilot study. Burns 2004; 30: 851-853.
170. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Ce-liker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19: 3137-3139.
171. Bergasa NV, Mcgee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 2006; 44: 1317-1323.
172. Vila T, Gommer J, Scates AC. Role of gabapentin in the treatment of uremic pruritus. Ann pharmacother 2008; 42: 1080-1084.
173. Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. Ren Fail 2009; 31: 85-90.
174. Porzio G, Aielli F, Verna L, Porto C, Tudini M, Cannita K, et al. Effcacy of pregabalin in the management of cetuximab-related itch. J pain Symptom Manage 2006; 32: 397-398.
175. Ehrchen J, Ständer S. Pregabalin in the treatment of chronic pruritus. J Am Acad Dermatol 2008; 58: 36-37.
176. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. J ren Care 2010; 36: 180-185.
177. Paus R, Schmelz M, Biro T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006; 116: 1174-1186.
178. Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J pain Symptom Manage 2003; 26: 1105-1112.
179. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J pain Symptom Manage 2003; 25: 288-291.
180. Shohrati M, Tajik A, Harandi AA, Davoodi SM, Akmasi M. Comparison of hydroxyzine and doxepin in treatment of pruritus due to sulfur mustard. Skinmed 2007; 6: 70-72.
181. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002; 99: 2627.
182. Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J pain Symptom Manage 1998; 16: 121-124.
183. Weisshaar E. Intractable chronic pruritus in a 67-year-old man. Acta Derm Venereol 2008; 88: 488-490.
184. Biondi M, Arcangeli T, Petrucci RM. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother psychosom 2000; 69: 165-166.
185. Mazzatenta C, peonia G, Martini P. Pruritus induced by interruption of paroxetine therapy. Br J Dermatol 2004; 150: 787.
186. Ständer S, Bockenholt B, Schurmeyer-horst F, Weishaupt C, Heuft G, Luger TA, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fuvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89: 45-51.
187. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a frst-line treatment for cholestatic pruritus. Hepatology 2007; 45: 666-674.
188. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-hT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61: 33-37.
189. Schworer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993; 341: 1277.
190. Schworer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Investig 1993; 71: 659-662.
191. Andrews PA, Quan V, Ogg CS. Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 1995; 10: 140.
192. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999; 354: 397.
193. Raderer M, Muller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994; 330: 1540.
194. Albares MP, Betlloch I, Guijarro J, Vergara G, Pascual JC, Botella R. Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. Br J Dermatol 2003; 148: 376-377.
195. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J gastroenterol hepatol 1998; 10: 865-870.
196. O'Donohue JW, Haigh C, Williams R. Ondansetron in the treatment of cholestasis: a randomised controlled trial. Gastroenterology 1997; 112: A1349.
197. Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996; 16: 958-960.
198. Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. Anesthesiology 1999; 90: 432-436.
199. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001; 18: 346-357.
200. Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CApD-pruritic patients. Nephron 1998; 78: 395-402.
201. Weisshaar E, Dunker N, Rohl FW, Gollnick H. Antipruritic effects of two different 5-hT3 receptor antagonists and an antihistamine in haemodialysis patients. Exp Dermatol 2004; 13: 298-304.
202. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystyn H. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J kidney Dis 2000; 35: 827-831.
203. Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003; 148: 314-317.
204. Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol 2000; 80: 24-25.
205. van den broek H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980; 116: 571-572.
206. Arrese JE, Dominguez-Soto L, Hojyo-Tomoka MT, Vega-Memije E, Cortes-Franco R, Guevara E, et al. Effectors of infammation in actinic prurigo. J Am Acad Dermatol 2001; 44: 957-961.
207. Winkelmann RK, Connolly SM, Doyle JA, Padilha-goncalves A. Thalidomide treatment of prurigo nodularis. Acta Derm Venereol 1984; 64: 412-417.
208. Johnke H, Zachariae H. Thaildomide treatment of prurigo nodularis. Ugeskr Laeger 1993; 155: 3028-3030.
209. Ferrandiz C, Carrascosa JM, Just M, Bielsa I, Ribera M. Sequential combined therapy with thalidomide and narrow-band (TL01) UVb in the treatment of prurigo nodularis. Dermatology 1997; 195: 359-361.
210. Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodefciency virus-infected subjects: effcacy and risk of neuropathy. Arch Dermatol 2004; 140: 845-849.
211. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lu-gon JR. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994; 67: 270-273.
212. Gaspari A. Thalidomide neurotoxicity in dermatological patients: the next "STEp. J Invest Dermatol 2002; 119: 987-988.
213. van Joost T, Stolz E, Heule F. Effcacy of low-dose cyclosporin in severe atopic skin disease. Arch Dermatol 1987; 123: 166-167.
214. Wahlgren CF, Scheynius A, Hägermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990; 70: 323-329.
215. Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to Cyclosporin. BR J Dermatol 1995; 132: 795-799.
216. Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol ges 2008; 6: 941-946.
217. Teofoli P, De pita O, Frezzolini A, Lotti T. Antipruritic effect of oral cyclosporin A in essential senile pruritus. Acta Derm Venereol 1998; 78: 232.
218. Calikoglu E, Anadolu R. Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin. Acta Derm Venereol 2002; 82: 380-382.
219. Fusaro M, Munaretto G, Spinello M, gallieni M. Regression of uraemic pruritus by cyclosporin treatment in a haemodialysis patient. Nephrol Dial Transplant 2004; 19: 1338-1339.
220. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010; 363: 397-398.
221. Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer 2010; 18: 1229-1230.
222. Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol 2012; 66: 14-15.
223. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 2011; 164: 665-667.
224. Ständer S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLOS one 2010; 5: e10968.
225. Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. Dermatol Ther 2005; 18: 344-354.
226. Jekler J, Larko O. UVb phototherapy of atopic dermatitis. Br J Dermatol 1988; 119: 697-705.
227. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet b and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357: 2012-2016.
228. Jekler J, Larko O. UVA solarium versus UVb phototherapy of atopic dermatitis: a paired-comparison study. Br J Dermatol 1991; 125: 569-572.
229. Legat FJ, Hofer A, Brabek E, Quehenberger F, Kerl H, Wolf P. Narrowband UV-b vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis. Arch Dermatol 2003; 139: 223-224.
230. Gambichler T, Hyun J, Sommer A, Stucker M, Altmeyer P, Kreuter A. A randomised controlled trial on photo(chemo) therapy of subacute prurigo. Clin Exp Dermatol 2006; 31: 348-353.
231. Szepietowski JC, Morita A, Tsuji T. Ultraviolet b induces mast cell apoptosis: a hypothetical mechanism of ultraviolet b treatment for uraemic pruritus. Med hypotheses 2002; 58: 167-170.
232. Wallengren J, Sundler F. Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fbres. Acta Derm Venereol 2004; 84: 111-115.
233. Saltzer EJ, Grove G. Relief from uremic pruritus: a therapeutic approach. Cutis 1975; 16: 298-299.
234. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 1977; 297: 136-138.
235. Taylor R, Taylor AE, Diffey BL, Hindson TC. A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron 1983; 33: 14-16.
236. Berne B, Vahlquist A, Fischer T, Danielson BG, Berne C. UV treatment of uraemic pruritus reduces the vitamin A content of the skin. Eur J Clin Invest 1984; 14: 203-206.
237. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979; 91: 17-21.
238. Ada S, Seckin D, Budakoglu I, Ozdemir FN. Treatment of uremic pruritus with narrowband ultraviolet b phototherapy: an open pilot study. J Am Acad Dermatol 2005; 53: 149-151.
239. Seckin D, Demircay Z, Akin O. Generalized pruritus treated with narrowband UVb. Int J Dermatol 2007; 46: 367-370.
240. Hsu MM, Yang CC. Uraemic pruritus responsive to broadband ultraviolet (UV) b therapy does not readily respond to narrowband UVb therapy. Br J Dermatol 2003; 149: 888-889.
241. Baldo A, Sammarco E, Plaitano R, Martinelli V, Mon-frecola. Narrowband (TL-01) ultraviolet b phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002; 147: 979-981.
242. Jahn S, Von Kobyletzki G, Behrens S, Röchling A, Altmeyer P, Kerscher M. Erfolgreiche behandlung des aquagenen pruritus mit pUVA-bad-photochemotherapie. Z hautkr 1997; 72: 821-824.
243. Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, Sanchez-pedreno P, Aliaga A. Treatment of aquagenic urticaria with pUVA and astemizole. J Am Acad Dermatol 1997; 36: 118-119.
244. Menage HD, Norris PG, Hawk JL, graves MW. The effcacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. Br J Dermatol 1993; 129: 163-165.
245. Xifra A, Carrascosa JM, Ferrandiz C. Narrow-band ultraviolet b in aquagenic pruritus. Br J Dermatol 2005; 153: 1233-1234.
246. Lim HW, Vallurupalli S, Meola T, Soter NA. UVb phototherapy is an effective treatment for pruritus in patients infected with hIV. J Am Acad Dermatol 1997; 37414-37417.
247. Kaptanoglu AF, Oskay T. Ultraviolet b treatment for pruritus in hodgkin's lymphoma. J Eur Acad Dermatol Venereol 2003; 17: 489-490.
248. Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVb: is it effective and safe for paedia-tric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol 2011; 25: 727-729.
249. Rosenbaum MS, Ayllon T. The behavioral treatment of neurodermatitis through habit-reversal. Behav res Ther 1981; 19: 313-318.
250. Gieler U, Kupfer J, Niemeier V, Brosig B, Stangier U. Atopic eczema prevention programs - a new therapeutic concept for secondary prevention. Dermatol psychosom 2000; 1: 138-147.
251. Staab D, Von Rueden U, Kehrt R, Erhart M, Wenninger K, Kamtsiuris P, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol 2002; 13: 84-90.
252. Stangier U, Ehlers A, Gieler U. Ppredicting long-term outcome in group treatment of atopic dermatitis. Psychother psychosom 2004; 73: 293-301.
253. Evers AW, Duller P, De Jong EM, Otero ME, Verhaak CM, van der Valk PG, et al. Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis. Acta Derm Venereol 2009; 89: 57-63.
254. Bathe A, Matterne U, Dewald M, Grande T, Weisshaar E. Educational multidisciplinary trainingprogramme for patients with chronic pruritus. Acta Derm Venereol 2009; 89: 498-501.
255. Hoegl L, Fichter M, Plewig G. Stationare Verhaltensme-dizin bei chronischen hautkrankheiten. Hautarzt 1998; 49: 270-275.
256. Lange S, Zschocke I, Langhardt S, Amon U, Augustin M. Effekte kombinierter therapeutischer Massnahmen bei patienten mit psoriasis und atopischer Dermatitis. Hautarzt 1999; 50: 791-797.
257. Gupta MA. Evaluation and treatment of "psychogenic"pruritus and self-excoriation. J Am Acad Dermatol 1995; 32: 532-533.
258. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15: 351-359.
259. Phillips LG, Robson MC. Pruritus in burns. Comments from Detroit receiving hospital, Detroit, Michigan. J burn Care rehabil 1988; 9: 308-309.
260. Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectr 2002; 7: 453-460, 63.
261. Chen YC, Chiu WT, Wu MS. Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. Am J kidney Dis 2006; 48: 69-76.
262. Che-yi C, Wen CY, Min-Tsung K, Chiu-Ching H. Acupuncture in haemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus. Nephrol Dial Transplant 2005; 20: 1912-1915.
263. De Marchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma hista-mine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992; 326: 969-974.
264. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 1053-1060.
265. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-493.
266. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Effcacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J hepatol 2002; 37: 717-722.
267. McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J hepatol 1994; 21: 496-499.
268. Raiford DS. Pruritus of chronic cholestasis. QJM 1995; 88: 603-607.
269. Walt RP, Daneshmend TK, Fellows IW, Toghill PJ. Effect of stanozolol on itching in primary biliary cirrhosis. BMJ 1988; 296: 607.
270. Fleischer AB, Jr. The clinical management of itching. New york, London: parthenon publishing; 2000.
271. Bergasa NV, Link MJ, keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy refected toward the eyes for the pruritus of chronic liver disease. Am J gastroenterol 2001; 96: 1563-1570.
272. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004; 49: 1-4.
273. Doria C, Mandala L, Smith J, Vitale CH, Lauro A, grutta-dauria S, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003; 9: 437-443.
274. Mullhaupt B, Kullak-Ublick GA, Ambuhl PM, Stocker R, Renner EL. Successful use of the Molecular Adsorbent recirculating System (MArS) in a patient with primary biliary cirrhosis (pbC) and treatment refractory pruritus. Hepatol res 2003; 25: 442-446.
275. Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004; 10: 107-114.
276. Bellmann R, Feistritzer C, Zoller H, Graziadei IW, Schwaighofer h, propst A, et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases. ASAIo J 2004; 50: 387-391.
277. Acevedo Ribo M, Moreno Planas JM, Sanz Moreno C, Rubio Gonzalez EE, Rubio Gonzalez E, Boullosa Grana E, et al. Therapy of intractable pruritus with MArS. Transplant proc 2005; 37: 1480-1481.
278. Montero JL, Pozo JC, Barrera P, Fraga E, Costan G, Dominguez JL, et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MArS). Transplant proc 2006; 38: 2511-2513.
279. Neuberger J. Liver Transplantation for Cholestatic Liver Disease. Curr Treat options gastroenterol 2003; 6: 113-121.
280. Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002; 11: 12-24.
281. Brune A, Metze D, Luger TA, Ständer S. Antipruritische Therapie mit dem oralen opiatrezeptorantagonisten Nal-trexon. offene, nicht placebokontrollierte Anwendung bei 133 patienten. Hautarzt 2004; 55: 1130-1136.
282. Fjellner B, Hagermark O. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta Derm Venereol 1979; 59: 505-512.
283. Easton P, Galbraith PR. Cimetidine treatment of pruritus in polycythemia vera. The N Engl J Med 1978; 299: 1134.
284. Weick JK, Donovan PB, Najean Y, Dresch C, Pisciotta AV, Cooperberg AA, et al. The use of cimetidine for the treatment of pruritus in polycythemia vera. Arch Intern Med 1982; 142: 241-242.
285. Fitzsimons EJ, Dagg JH, McAllister EJ. Pruritus of po-lycythaemia vera: a place for pizotifen? BMJ 1981; 283: 277.
286. Chanarin I, Szur L. Letter: relief of intractable pruritus in polycythaemia rubra vera with cholestyramine. Br J haematol 1975; 29: 669-670.
287. Swerlick RA. Photochemotherapy treatment of pruritus associated with polycythemia vera. J Am Acad Dermatol 1985; 13: 675-677.
288. Jeanmougin M, Rain JD, Najean Y Effcacy of photochemotherapy on severe pruritus in polycythemia vera. Ann hematol 1996; 73: 91-93.
289. Tinegate H, McLelland J. Transcutaneous electrical nerve stimulation may improve pruritus associated with haematological disorders. Clin Lab haematol 2002; 24: 389-390.
290. De Wolf JT, Hendriks DW, Egger RC, Esselink MT, Halie MR, Vellenga E. Alpha-interferon for intractable pruritus in polycythaemia vera. Lancet 1991; 337: 241.
291. Muller EW, De Wolf JT, Egger R, Wijermans PW, Huijgens PC, Halie MR, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J haematol 1995; 89: 313-318.
292. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J hematol 1993; 43: 316-318.
293. Taylor PC, Dolan G, NG JP, Paul B, Collin R, Reilly JT. Effcacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br J haematol 1996; 92: 55-59.
294. Shelley WB, Shelley ED. Aquadynia: noradrenergic pain induced by bathing and responsive to clonidine. J Am Acad Dermatol 1998; 38: 357-358.
295. Wolf R, Krakowski A. Variations in aquagenic pruritus and treatment alternatives. J Am Acad Dermatol 1988; 18: 1081-1083.
296. Steinman HK, Greaves MW. Aquagenic pruritus. J Am Acad Dermatol 1985; 13: 91-96.